JP2023519851A5 - - Google Patents
Info
- Publication number
- JP2023519851A5 JP2023519851A5 JP2022558065A JP2022558065A JP2023519851A5 JP 2023519851 A5 JP2023519851 A5 JP 2023519851A5 JP 2022558065 A JP2022558065 A JP 2022558065A JP 2022558065 A JP2022558065 A JP 2022558065A JP 2023519851 A5 JP2023519851 A5 JP 2023519851A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence number
- ctat
- seq
- bispecific antibody
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025135194A JP2025161873A (ja) | 2020-03-23 | 2025-08-14 | 武装免疫細胞を産生する際に使用するための二重特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993080P | 2020-03-23 | 2020-03-23 | |
| US62/993,080 | 2020-03-23 | ||
| PCT/US2021/023655 WO2021195067A1 (en) | 2020-03-23 | 2021-03-23 | Bi-specific antibodies for use in producing armed immune cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135194A Division JP2025161873A (ja) | 2020-03-23 | 2025-08-14 | 武装免疫細胞を産生する際に使用するための二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519851A JP2023519851A (ja) | 2023-05-15 |
| JP2023519851A5 true JP2023519851A5 (https=) | 2024-04-02 |
| JP7729833B2 JP7729833B2 (ja) | 2025-08-26 |
Family
ID=77892613
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022558065A Active JP7729833B2 (ja) | 2020-03-23 | 2021-03-23 | 武装免疫細胞を産生する際に使用するための二重特異性抗体 |
| JP2025135194A Pending JP2025161873A (ja) | 2020-03-23 | 2025-08-14 | 武装免疫細胞を産生する際に使用するための二重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135194A Pending JP2025161873A (ja) | 2020-03-23 | 2025-08-14 | 武装免疫細胞を産生する際に使用するための二重特異性抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240209084A1 (https=) |
| EP (1) | EP4126954A4 (https=) |
| JP (2) | JP7729833B2 (https=) |
| CN (1) | CN115551890A (https=) |
| AU (1) | AU2021244375A1 (https=) |
| IL (1) | IL296566A (https=) |
| TW (1) | TWI904147B (https=) |
| WO (1) | WO2021195067A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| TW202323295A (zh) * | 2021-08-11 | 2023-06-16 | 賽昂生醫股份有限公司 | 用於產生武裝免疫細胞的方法 |
| WO2023143478A1 (en) * | 2022-01-27 | 2023-08-03 | Crown Bioscience Inc. | Novel anti-cd4 and anti-pd-l1 bispecific antibodies |
| CN118005806B (zh) * | 2024-02-08 | 2026-01-30 | 北京市眼科研究所 | 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用 |
| CN121248779A (zh) * | 2024-06-25 | 2026-01-02 | 冕屹立生物技术(上海)有限公司 | 靶向人cd3分子的抗体及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US20060134105A1 (en) * | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| CN104379169A (zh) * | 2012-08-14 | 2015-02-25 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
| US9611325B2 (en) * | 2014-07-21 | 2017-04-04 | Wuhan Yzy Biopharma Co., Ltd. | Construction and application of bispecific antibody HER2xCD3 |
| JP6871155B2 (ja) * | 2014-07-25 | 2021-05-12 | メモリアル スローン ケタリング キャンサー センター | 二重特異性ｈｅｒ２及びｃｄ３結合分子 |
| KR102614189B1 (ko) * | 2014-11-17 | 2023-12-18 | 리제너론 파아마슈티컬스, 인크. | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 |
| CN104829725A (zh) * | 2015-01-21 | 2015-08-12 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体cd133×cd3的构建及应用 |
| CN108348551A (zh) * | 2015-08-28 | 2018-07-31 | 宾夕法尼亚大学董事会 | 表达嵌合细胞内信号传导分子的细胞的方法和组合物 |
| WO2017077382A1 (en) * | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| WO2018049248A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
| CN106632681B (zh) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | 抗egfr和抗cd3双特异抗体及其应用 |
| KR102367658B1 (ko) * | 2017-03-29 | 2022-02-25 | 타이페이 메디컬 유니이버시티 | 항원 특이적 t 세포 및 그의 용도 |
| EP3802595A1 (en) * | 2018-06-07 | 2021-04-14 | OncoOne Research & Development GmbH | Anti-oxmif/anti-cd3 antibody for cancer treatment |
-
2021
- 2021-03-23 IL IL296566A patent/IL296566A/en unknown
- 2021-03-23 AU AU2021244375A patent/AU2021244375A1/en active Pending
- 2021-03-23 TW TW110110483A patent/TWI904147B/zh active
- 2021-03-23 CN CN202180029464.3A patent/CN115551890A/zh active Pending
- 2021-03-23 WO PCT/US2021/023655 patent/WO2021195067A1/en not_active Ceased
- 2021-03-23 JP JP2022558065A patent/JP7729833B2/ja active Active
- 2021-03-23 EP EP21774346.7A patent/EP4126954A4/en active Pending
- 2021-03-23 US US17/913,775 patent/US20240209084A1/en active Pending
-
2025
- 2025-08-14 JP JP2025135194A patent/JP2025161873A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519851A5 (https=) | ||
| Felices et al. | Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells | |
| KR102777002B1 (ko) | 항글리피칸-3 항체 및 이의 응용 | |
| JP7461950B2 (ja) | Ｃｄ３抗体およびその医薬用途 | |
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| CN107880128B (zh) | 一种抗cd19的全人源抗体或抗体片段及其方法和应用 | |
| RU2019110835A (ru) | Антитела к pd-1(cd279) | |
| Omidfar et al. | Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody | |
| JP2015527070A5 (https=) | ||
| CN109055380B (zh) | 一种通用型car-t细胞的制备方法 | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2022548796A5 (https=) | ||
| CN103833852A (zh) | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 | |
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| WO2017121758A1 (en) | Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| CN104829725A (zh) | 一种双特异性抗体cd133×cd3的构建及应用 | |
| TW201920272A (zh) | 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用 | |
| JP7052149B2 (ja) | 新型構造の抗ｖｅｇｆ－抗ｐｄ１二重特異性抗体 | |
| IL320882A (en) | And the uses of PSMA antibodies | |
| CN104288765A (zh) | 一种利用具有中和FLT3生物学活性的McAb应用于肿瘤的靶向治疗的新方法 | |
| JP2024540863A5 (https=) | ||
| CN114258402B (zh) | 抗cd123抗体、抗cd123嵌合抗原受体和抗cd123嵌合抗原受体t细胞 | |
| Pfeifer Serrahima et al. | Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies |